Compare Adaptive Biotechnologies Corp (ADPT) vs Carlyle Group Inc (CG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Carlyle Group Inc — how do they compare? Adaptive Biotechnologies Corp trades at $19.96 (market cap $3.33B), while Carlyle Group Inc trades at $42.94 (market cap $15.84B). The key difference: Carlyle Group Inc is far larger — about 4.8× Adaptive Biotechnologies Corp's market cap, and Carlyle Group Inc pays a 3.18% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | CG | |
|---|---|---|
Market Cap | $3.33B | $15.84B |
Sector | Health | Financials |
52-Week High | $22.37 | $69.35 |
52-Week Low | $10.24 | $40.52 |
Enterprise Value | $3.19B | — |
Dividend Yield | — | 3.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Carlyle Group (CG) trades at $44.01, up 2.76% with a P/E of 30.16 and P/S of 5.61. Recent earnings show mixed results with Q4 2025 beat but Q1 2026 miss. Technical indicators signal bearish momentum with RSI at 76.93 suggesting overbought conditions. The company maintains strong analyst support with 14 buy ratings and a $59.60 consensus price target, representing 35% upside potential from current levels.
Carlyle demonstrates solid profitability with 18.85% net margin and 9.95% ROE, though revenue declined to $3.21B in 2025. Key risks include volatile cash flow from operations and execution challenges in fundraising targets. The stock offers growth potential through strategic acquisitions like MAI Capital Management, but investors should monitor earnings consistency and private credit exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Carlyle Group Inc
The Carlyle Group is one of the world's largest alternative-asset managers, with $376.4 billion in total assets under management, including $259.6 billion in fee-earning AUM, at the end of June 2022. The company has three core business segments: private equity, which includes private equity, real estate, infrastructure and natural resources funds (accounting for 41% of fee-earning AUM and 65% of base management fees during 2021), global credit (45% and 24%) and investment solutions (14% and 11%). The firm primarily serves institutional investors and high-net-worth individuals. Carlyle operates through 29 offices across five continents, serving close to 2,700 active carry fund investors from 95 countries.
Read more on CG →
